Mather P J, Silberstein S D, Schulman E A, Hopkins M M
Department of Medicine, Temple University Hospital, Philadelphia, PA.
Headache. 1991 Sep;31(8):525-32. doi: 10.1111/j.1526-4610.1991.hed3108525.x.
We reviewed our experience with 54 cluster headache patients (23 episodic, 31 chronic) admitted to our headache center 64 tines over the past five years and treated with repetitive intravenous dihydroergotamine (IV DHE). DHE therapy was initiated on admission and prophylactic medication regimens were started or adjusted. All 54 patients had complete relief of their cluster headache, usually within two days. Most (82.8%) had no side effects. The average length of hospitalization was 6.7 days. At the three month followup, 92.9% of the episodic cluster patients were headache-free and 7.1% had a 50-74% improvement; at six months, all were headache-free. Of the chronic cluster patients, 44.4% were headache-free at three months and 52.8% had at least 50% improvement. At six months, 75% were headache-free and 22.2% were at least 75% improved, probably as a result of continued prophylactic medication. Repetitive IV DHE safely, rapidly, and effectively controls cluster headache.
我们回顾了过去五年间64次收治于我们头痛中心的54例丛集性头痛患者（23例发作性，31例慢性）的治疗经验，这些患者均接受了重复静脉注射双氢麦角胺（IV DHE）治疗。DHE治疗在入院时开始，预防性用药方案也同时启动或调整。所有54例患者的丛集性头痛均完全缓解，通常在两天内。大多数（82.8%）患者无副作用。平均住院时间为6.7天。在三个月的随访中，92.9%的发作性丛集性头痛患者无头痛发作，7.1%有50%-74%的改善；在六个月时，所有患者均无头痛发作。在慢性丛集性头痛患者中，44.4%在三个月时无头痛发作，52.8%至少有50%的改善。在六个月时，75%无头痛发作，22.2%至少有75%的改善，这可能是持续预防性用药的结果。重复静脉注射DHE能安全、快速且有效地控制丛集性头痛。
